Welcome back to Money Movers. Take a look at the XBI biotech ETF on pace for its best year since 2020. And news breaking earlier from the Wall Street Journal that Johnson and Johnson is looking to buy Protagonist Therapeutics.Our ne next guest is a top shareholder in Protagonist and a longtime investor in the biotech space. Joining us now, RTW Investments managing partner and CIO, Dr. . Rod Wong.Dr. . Thank you for being here today. Um, so there's been a a string of acquisitions in this space in in recent w ...

Investment Overview - Cigna Group's Evernorth Health Services announced a $3.5 billion investment in Shields Health Solutions, a specialty pharmacy management company [1] - The investment coincided with Shields' establishment as a private, stand-alone company following its acquisition by Sycamore Partners, which previously acquired Walgreens Boots Alliance, Shields' former owner [1] Financial Impact - The investment in Shields was made in the form of preferred stock and is not expected to materially impact Cigna's previously issued 2025 adjusted EPS guidance of at least $29.60 [2] - BofA Securities noted that Cigna is a pure-play commercial insurer, maintaining a long-term EPS growth outlook [2] Market Position and Growth - Cigna's large pharmacy benefits and specialty drug businesses provide broad exposure to rising drug spending, including obesity treatments, biosimilars, and gene therapies, without reliance on individual products [3] - Analyst Kevin Fischbeck projects EPS growth of 10%–15% annually, with a 9% free cash flow yield, while avoiding regulatory risks faced by peers, supporting expected returns of 10–15% [3] Stock Performance - Cigna Group's stock was reported to be up 0.22% at $301.65 at the time of publication [6]

Group 1 - Rocket Pharmaceuticals is positioned as a compelling gene therapy company due to its focus on therapies that provide a life-long effect, particularly in cardiovascular and hematology areas, contrasting with many gene therapies that have limited durability, especially those targeting the liver [1] - The company may initiate a beneficial long position in its stock or related derivatives within the next 72 hours, indicating potential investor interest and confidence in its future performance [1]